Carderock Capital Management Inc. cut its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 5.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,769 shares of the company's stock after selling 718 shares during the period. Carderock Capital Management Inc.'s holdings in IDEXX Laboratories were worth $5,693,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. FSA Wealth Management LLC acquired a new position in shares of IDEXX Laboratories during the 3rd quarter valued at about $25,000. E Fund Management Hong Kong Co. Ltd. grew its holdings in IDEXX Laboratories by 5,700.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company's stock valued at $29,000 after buying an additional 57 shares during the last quarter. Mowery & Schoenfeld Wealth Management LLC grew its holdings in IDEXX Laboratories by 750.0% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company's stock valued at $34,000 after buying an additional 60 shares during the last quarter. Strategic Investment Solutions Inc. IL acquired a new stake in IDEXX Laboratories in the 2nd quarter valued at approximately $36,000. Finally, Ashton Thomas Securities LLC acquired a new stake in IDEXX Laboratories in the 3rd quarter valued at approximately $37,000. 87.84% of the stock is owned by hedge funds and other institutional investors.
IDEXX Laboratories Trading Down 2.2 %
Shares of IDXX traded down $9.36 during trading hours on Friday, hitting $419.26. 798,777 shares of the stock traded hands, compared to its average volume of 426,678. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $583.39. The firm has a market capitalization of $34.33 billion, a PE ratio of 40.43, a price-to-earnings-growth ratio of 3.52 and a beta of 1.36. The business has a fifty day moving average of $423.88 and a 200-day moving average of $458.53.
IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings data on Thursday, October 31st. The company reported $2.80 EPS for the quarter, beating analysts' consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. During the same quarter in the prior year, the company posted $2.53 earnings per share. The firm's revenue was up 6.6% on a year-over-year basis. Analysts expect that IDEXX Laboratories, Inc. will post 10.44 EPS for the current year.
Wall Street Analysts Forecast Growth
Several brokerages have recently weighed in on IDXX. Stifel Nicolaus decreased their price objective on IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating on the stock in a report on Thursday, October 10th. Barclays decreased their price objective on IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating on the stock in a report on Monday, November 4th. JPMorgan Chase & Co. decreased their price objective on IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating on the stock in a report on Friday, October 11th. Piper Sandler restated a "neutral" rating and set a $435.00 target price (down previously from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Finally, StockNews.com upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday, November 28th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $523.86.
Check Out Our Latest Analysis on IDXX
Insiders Place Their Bets
In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the sale, the director now directly owns 905 shares in the company, valued at $380,498.20. This represents a 27.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 2.18% of the company's stock.
About IDEXX Laboratories
(
Free Report)
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Recommended Stories
Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
